Our 2010 Stock Incentive Plan (as amended, the “2010 Plan”) under which our Company has granted stock options and other share-based payment awards of our Common Stock to eligible employees, directors, and consultants has expired. In total, 1,663,731 shares of Class A Common Stock were issued or reserved for issuance pursuant to the previously granted options or restricted stock units under that plan.

On November 4, 2020, the Company enacted the 2020 Stock Incentive Plan (the “2020 Plan”). Under the 2020 Plan, the Company may grant stock options and other share-based payment awards of our Class A Common Stock to eligible employees, directors and consultants. The aggregate total number of shares of Class A Common Stock authorized for issuance under the 2020 Plan at December 31, 2020 was 1,250,000, of which 1,096,394 remain available for future issuance, and 200,000 shares of Class B stock. In addition, if any awards that were outstanding under the 2010 Plan as of November 3, 2020 are subsequently forfeited or if the related shares are repurchased, a corresponding number of shares will automatically become available for issuance under the 2020 Plan, thus resulting in an increase in the number of shares available for issuance under the 2020 Plan (up to an additional 1,024,902 shares of Class A Stock).

Stock options are granted at exercise prices equal to the grant-date market prices and typically expire no later than five years from the grant date. In contrast to a stock option where the grantee buys our Company’s share at an exercise price determined on grant date, a restricted stock unit (“RSU”) entitles the grantee to receive one share for every RSU based on a vesting plan, typically between one and four years from grant. At the time the options are exercised or RSUs vest and are settled, at the discretion of management, we will issue treasury shares or make a new issuance of shares to the option or RSU holder.

We have estimated the grant-date fair value of our stock options using the Black-Scholes option-valuation model, which takes into account assumptions such as the dividend yield, the risk-free interest rate, the expected stock price volatility, and the expected life of the options. We expensed the estimated grant-date fair values of options over the vesting period on a straight-line basis. Based on our historical experience, the “deemed exercise” of expiring in-the-money options and the relative market price to strike price of the options, we have not estimated any forfeitures of vested or unvested options.

The weighted average assumptions used in the option-valuation model for the years 2020, 2019 and 2018 were as follows:

We recorded stock-based compensation expense of $460,000, $458,000, and $425,000 for 2020, 2019, and 2018, respectively. At December 31, 2020, the total unrecognized estimated compensation cost related to non-vested stock options was $650,000 which is expected to be recognized over a weighted average vesting period of 1.44 years. No cash was received from option exercises in 2020. Cash consideration received from option exercises during 2019 and 2018 totaled $906,000 and $361,000 respectively.

The following is a summary of the status of RDI’s outstanding stock options for the three years ended December 31, 2020:



	Outstanding Stock Options
	Number of ‎Options		Weighted Average ‎Exercise Price				Weighted Average ‎Remaining Years of ‎Contractual Life	Aggregate ‎Intrinsic ‎Value
	Class A	Class B	Class A		Class B		Class A&B	Class A&B
Outstanding - January 1, 2018	524,589	—	$	12.50	$	—	3.15	$	3,054,325
Granted	126,840	—		16.40		—
Exercised	(60,000)	—		6.02		—			610,249
Expired	(4,960)	—		12.08		—
Outstanding - December 31, 2018	586,469	—	$	14.01	$	—	2.88	$	1,530,528
Granted	219,408	—		16.12		—
Exercised	(69,500)	—		13.42		—			185,175
Expired	(25,000)	—		13.42		—
Outstanding - December 31, 2019	711,377	—	$	14.74	$	—	2.79	$	136,350
Granted	38,803	—		4.66		—
Exercised	—	—		—		—			—
Expired	(36,701)	—		14.74		—
Outstanding - December 31, 2020	713,479	—	$	14.64	$	—	2.18	$	13,969

The following is a summary of the status of RDI’s vested and unvested stock options as of December 31, 2020, 2019 and 2018:



	Vested and Unvested Stock Options
	Number of ‎Options		Weighted Average ‎Exercise Price				Weighted Average ‎Remaining Years of ‎Contractual Life	Aggregate ‎Intrinsic ‎Value
	Class A	Class B	Class A			Class B	Class A&B	Class A&B
Vested
December 31, 2020	418,435	—	$	13.87	$	—	1.64	$	—
December 31, 2019	273,866	—		12.59		—	1.87		136,350
December 31, 2018	231,124	—		12.38		—	2.28		1,306,643
Unvested
December 31, 2020	295,044	—	$	15.77	$	—	2.47	$	13,969
December 31, 2019	437,511	—		15.78		—	3.36		—
December 31, 2018	355,345	—		15.07		—	3.27		223,885

Restricted Stock Units

RSU awards to Management vest 25% on the anniversary of the grant date over a period of four years. Beginning this year, a performance component has been added to certain of the RSUs granted to Management. On March 10, 2020, RSUs covering 287,163 shares were issued to members of executive Management and other employees of our Company. Between December 14, 2020 and December 16, 2020, RSUs covering 114,803 shares were issued to members of executive Management and other employees of our Company, all of which vest 100% on the anniversary of the grant date over a period of one year.

We estimate the grant-date fair values of our RSUs using the Company’s stock price at grant-date and record such fair values as compensation expense over the vesting period on a straight-line basis. Prior to November 7, 2018, RSU awards to non-employee directors vested 100% in January of the following year in which such RSUs were granted. At the November 7, 2018 Board meeting, it was determined that it would be more appropriate for the vesting of RSUs to align with the director’s term of office. Accordingly, the RSUs granted on November 7, 2018, vested on the first to occur of (i) 5:00 pm, Los Angeles, CA time on the last business day prior to the one year anniversary of the grant date, or (ii) the date on which the recipient’s term as a director ended and the recipient or, as the case may be, the recipient’s successor was elected to the board of directors. Accordingly, the RSUs granted to directors on November 7, 2018 vested on May 7, 2019 annual meeting of stockholders. Due to the fact that our Company moved up our annual meeting of stockholders from November to May in 2019, the vesting period for the RSUs issued on November 7, 2018 was shorter than anticipated. In order to adjust for this factor, the award of RSUs to directors made immediately following the 2019 Annual Meeting of Stockholders was determined using a value of $35,000 or one half of the dollar amount of the prior year’s annual grant. The RSUs issued to non-employee directors on May 7, 2019 vested on May 6, 2020. We granted non-employee directors 60,084 RSUs on December 16, 2020.

During the years ended December 31, 2020 and December 31, 2019, we recognized compensation expense related to RSUs of $1.0 million and $1.0 million respectively. The total unrecognized compensation expense related to these unvested RSUs was $2.6 million as of December 31, 2020.

Below is a table that shows the restricted stock units that have been issued and vested during the years ending December 31, 2020 along with the dollar value of these awards:



	Number of RSUs					$ value of RSUs
	Granted	Vesting	Forfeited	Unvested	Granted		Vesting			Forfeited	Unvested
2016	68,153	67,372	781	—	$	815,160	$	805,760	$	9,400	$	—
2017	70,538	61,590	532	8,416		1,124,348		981,448		8,496		134,404
2018	97,600	74,292	2,102	21,206		1,581,512		1,199,232		34,240		348,040
2019	59,258	22,713	3,104	33,441		944,070		354,806		50,005		539,259
2020	401,966	—	818	401,148		1,756,002		—		5,002		1,751,000
Total	697,515	225,967	7,337	464,211	$	6,221,091	$	3,341,245	$	107,144	$	2,772,703

On March 14, 2019, the Board of Directors extended our Company’s stock repurchase program for two years, through March 2, 2021. The Board did not increase the authorized amount, which was initially fixed at $25.0 million. On March 10, 2020, the Board increased the authorized amount by $25.0 million and extended it to March 2, 2022. At the present time, the repurchase program authorization is $26.0 million.

The repurchase program allows Reading to repurchase its shares in accordance with the requirements of the SEC on the open market, in block trades and in privately negotiated transactions, depending on market conditions and other factors. All purchases are subject to the availability of shares at prices that are acceptable to Reading, and accordingly, no assurances can be given as to the timing or number of shares that may ultimately be acquired pursuant to this authorization.

Under the stock repurchase program, as of December 31, 2020, our Company had reacquired a total of 1,792,819 shares of Class A Non-Voting Common Stock for $24.0 million at an average price of $13.39 per share (excluding transaction costs). 75,157 shares of Class A Non-Voting Common Stock were purchased during the quarter ended March 31, 2020 at an average price of $8.92 per share. No shares have been repurchased since. The last share repurchase made by our Company was made on March 5, 2020, at which time 25,000 shares were purchased at an average cost per share of $7.30. This leaves $26.0 million available under the March 2, 2017 program, as extended, to March 2, 2022.